SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Glenmark Pharmaceuticals Ltd

BSE: 532296 NSE: GLENMARK ISIN: INE935A01035
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Glenmark Pharmaceuticals Ltd belong to?
Glenmark Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Glenmark Pharmaceuticals Ltd a good quality company?
Glenmark Pharmaceuticals Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Glenmark Pharmaceuticals Ltd undervalued or overvalued?
Glenmark Pharmaceuticals Ltd appears Overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Glenmark Pharmaceuticals Ltd a good buy now?
Glenmark Pharmaceuticals Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd revenue growth is 12.8% for FY-2025 , which is above its 5 year CAGR of 4.6% , indicating faster growth.
Q.2 Gross Profit margin of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is 7.7% for FY-2025 , which is above its 5 year median of 7.1% , indicating increasing margins.
Q.3 Operating Profit Margin of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 17.65% for FY-2025 , which is in line with its 5 year median of 17.65% indicating stable margins.
Q.4 Net Profit Margin of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd Net Profit Margin is 7.86% for FY-2025 , is in line with with its 5 year median of 7.86%, indicating stable margins.
Current Level Historic Median
Gross Profit Margin 7.7 7.1
Operating Profit Margin 17.65 17.65
Net Profit Margin 7.86 7.86
Q.5 Return on Asset of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd Return on Asset is 7.42%, which is above its 5 year historical median of 6.74%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd Return on equity is 12.56% for FY-2025 , which is above its historical median of 12.33%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd Return on capital employed is 16.16% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 11.25%, indicating value creation.
Q.8 Cash conversion cycle of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd Cash conversion cycle is -25 days, below its historical median of -21 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 2.08 1.85
ROE 12.56 12.33
ROCE 16.16 14.19
Cash Conversion Cycle -25 days -21 days
Q.9 Debt to Equity ratio of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd Debt-to-Equity ratio is 0.25 , which is above with the industry average of 0.13 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd Debt to cash flow from operations is -2.65 , which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Glenmark Pharmaceuticals Ltd?
Promoters hold 46.65% of the Glenmark Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Glenmark Pharmaceuticals Ltd vs industry peers?
Glenmark Pharmaceuticals Ltd revenue CAGR is 4.60% , compared to the industry median CAGR of 8.87% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 13,321.7 8,127.2
Gross Profit 1,025.8 1,337.7
Operating Profit 2,351 1,810
Net Profit 1,047 970
Operating Efficiency
Current Level Industry Median
Asset Turnover 2.08 0.8
ROE 12.56 18.61
ROCE 16.16 17.96
Cash Conversion Cycle (days) -24.61 76

Valuation & price assessment

Q.1 Stock return of Glenmark Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 11.1% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 11.1% 33.1% 66% 65.6%
Q.3 Valuation ratios of Glenmark Pharmaceuticals Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 59.39 13.60 40.28
Price to Book 6.34 4.41 2.77
Price to Sales 3.91 2.98 2.65
EV to EBITDA 13.21 12.32 15.67

Check more companies

1. Dr. Reddys Lab
2. Lupin
3. Zydus Lifesciences
4. Mankind Pharma
5. Aurobindo Pharma
6. Alkem Laboratories
7. Glenmark Pharma
8. Laurus Labs
9. Biocon
10. Abbott India
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×